Cubist Pharmaceuticals Inc. - Thread - 500 Beiträge pro Seite
eröffnet am 03.10.03 17:14:42 von
neuester Beitrag 07.10.03 15:24:11 von
neuester Beitrag 07.10.03 15:24:11 von
Beiträge: 5
ID: 782.612
ID: 782.612
Aufrufe heute: 0
Gesamt: 809
Gesamt: 809
Aktive User: 0
ISIN: US2296781071 · WKN: 909594
88,01
EUR
+0,04 %
+0,04 EUR
Letzter Kurs 16.01.15 Tradegate
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9000 | +59,66 | |
| 0,6000 | +57,48 | |
| 1,9200 | +23,87 | |
| 5,4500 | +19,00 | |
| 6,9300 | +17,46 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 4,3600 | -13,49 | |
| 1,6900 | -14,50 | |
| 2,8150 | -15,21 | |
| 1,7250 | -20,14 | |
| 2,2600 | -30,25 |
Feedback
NEW YORK, Oct 3 (Reuters) - Chiron Corp. (CHIR) agreed to pay Cubist Pharmaceuticals Inc. (CBST) up to $50 million for the right to develop and commercialize Cubist`s antibiotic drug, the companies said on Friday.
Chiron, a leading maker of vaccines and blood tests, will pay Cubist $18 million upfront, of which $10 million will be used to buy restricted Cubist common stock. The stock will be acquired for about $18.89 a share, or a 50 percent premium to the average price over the past 30 days.
Shares of Cubist jumped 80 cents, or 7.4 percent, to $11.60 in early trade on the Nasdaq.
Chiron will gain the right to market the drug, Cubicin, outside the United States. Cubicin was approved in the U.S last month for the treatment of severe skin infections. It has not yet been approved in Europe.
Cubist is also testing the drug in late-stage clinical trials for the treatment of a blood infection and infection of the sac around the heart.
Chiron will pay Cubist additional sums as it reaches certain regulatory and sales milestones, and will pay an undisclosed royalty on sales of the drug.
Craig Wheeler, president of Chiron BioPharmaceuticals, said Cubicin "fits well into Chiron`s portfolio of products to treat and prevent infectious disease."
Shares of Chiron rose 50 cents, or 0.9 percent to $54.43 in early Nasdaq trading.
Chiron, a leading maker of vaccines and blood tests, will pay Cubist $18 million upfront, of which $10 million will be used to buy restricted Cubist common stock. The stock will be acquired for about $18.89 a share, or a 50 percent premium to the average price over the past 30 days.
Shares of Cubist jumped 80 cents, or 7.4 percent, to $11.60 in early trade on the Nasdaq.
Chiron will gain the right to market the drug, Cubicin, outside the United States. Cubicin was approved in the U.S last month for the treatment of severe skin infections. It has not yet been approved in Europe.
Cubist is also testing the drug in late-stage clinical trials for the treatment of a blood infection and infection of the sac around the heart.
Chiron will pay Cubist additional sums as it reaches certain regulatory and sales milestones, and will pay an undisclosed royalty on sales of the drug.
Craig Wheeler, president of Chiron BioPharmaceuticals, said Cubicin "fits well into Chiron`s portfolio of products to treat and prevent infectious disease."
Shares of Chiron rose 50 cents, or 0.9 percent to $54.43 in early Nasdaq trading.
Der Gap nach oben sollte ziemlich bald geschlossen werden. Heute ist ein guter Anfang. Erst +7% durch gute Nachrichten, jetzt noch 4% im Plus, Tendenz steigend. Kursziel 13 USD.
Nasdaq
CBST
Vortag USD 10,80
Aktuell USD 11,25
Differenz USD + 0,450 +4,17%
Volumen USD 12,53 Mio.
1.209.700 gehandelte Aktien
CBST
Vortag USD 10,80
Aktuell USD 11,25
Differenz USD + 0,450 +4,17%
Volumen USD 12,53 Mio.
1.209.700 gehandelte Aktien
Morgen geht´s weiter!! 
SAN FRANCISCO, Oct 6 (Reuters)- Drug maker Cubist Pharmaceuticals Inc. (CBST) on Monday said it will offer to the public 5.6 million shares of its common stock related to a registration statement previously filed with the Securities and Exchange Commission.
Lexington, Massachusetts-based Cubist said it also intends to grant an option to the underwriters to purchase up to 840,000 additional shares of common stock solely to cover over- allotments.
Cubist said the sole book-runner for the offering is Morgan Stanley & Co. Inc. and that Pacific Growth Equities LLC is a co-lead manager and the offering`s co-managers are WR Hambrecht and Co. LLC and Harris Nesbitt Gerard Inc.
© Reuters 2003.
Lexington, Massachusetts-based Cubist said it also intends to grant an option to the underwriters to purchase up to 840,000 additional shares of common stock solely to cover over- allotments.
Cubist said the sole book-runner for the offering is Morgan Stanley & Co. Inc. and that Pacific Growth Equities LLC is a co-lead manager and the offering`s co-managers are WR Hambrecht and Co. LLC and Harris Nesbitt Gerard Inc.
© Reuters 2003.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -0,10 | |
| -3,45 | |
| +0,48 | |
| -1,23 | |
| -0,50 | |
| -0,21 | |
| +0,57 | |
| -1,12 | |
| -1,30 | |
| -1,73 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 223 | ||
| 99 | ||
| 91 | ||
| 80 | ||
| 53 | ||
| 47 | ||
| 45 | ||
| 42 | ||
| 41 | ||
| 32 |
